Will I relapse if I stop taking Ofatumumab?

Whether relapse occurs after discontinuation of Ofatumumab treatment depends on the specific disease and individual circumstances. Ofatumumab is a drug used to treat chronic lymphocytic leukemia and multiple sclerosis. It reduces disease progression by inhibiting B cell activity. If ofatumumab is discontinued, B cells may become reactivated, causing a recurrence of the disease.

After discontinuation of ofatumumab treatment, disease recurrence is possible. This is because the biological activity of monoclonal antibodies wanes over time, allowing malignant cells to repopulate. In addition, individual disease characteristics, molecular abnormalities, and other therapeutic interventions also influence the likelihood of recurrence. For each patient, the risk of relapse when discontinuing ofatumumab requires detailed discussion and evaluation with a physician. The doctor will develop the most appropriate treatment plan based on the characteristics of the disease, treatment history, and the patient's overall health. Before determining a discontinuation plan, it is recommended to follow the doctor's advice and conduct monitoring and follow-up in accordance with the prescribed treatment plan.

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.